TrialESMO open2022

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.

C Vicier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.